Stimulants work by forcing dopamine output from a finite pool. The crash is built into the mechanism — a resource drawn down, not built up. Semax works differently: it upregulates BDNF, the growth signal the brain uses to form new connections, strengthen existing ones, and maintain the infrastructure that makes sustained attention feel effortless rather than forced. The same pathway exercise activates, studied by subcutaneous injection and nasal-spray routes.
The trade-off is time. Effects build over 3–5 days as gene expression shifts and peak during days 7–14 of each cycle — not the 45-minute onset people expect from Adderall. Semax has been a registered pharmaceutical in Russia since 1994, used first for stroke recovery and then broadly for cognitive restoration after illness, surgery, and demanding knowledge work. No Western RCTs exist — not because of safety signals, but because unpatentable peptides don't attract the $50M+ required to run them.
Its standard pairing with Selank replaces the stimulant-plus-anxiolytic pattern — Adderall for focus, something else for the anxiety it creates — with complementary mechanisms that address both without the trade-offs of either.
| At a Glance | |
|---|---|
| Dosage | 200–600 µg subcutaneous, morning dosing. Nasal spray is an alternative route at the same dose range. |
| Protocol | 10–14 days on, 2–3 days off. The common pattern opens at 200 µg for 3–5 days, then runs at 300–400 µg/day. |
| Results timeline | Effects build over the first 3–5 days as gene expression changes accumulate, with focus and cognitive clarity peaking during days 7–14 of each cycle. |
| Side effects | Mildly activating — dosing after early afternoon can disrupt sleep. No cardiovascular strain, no crash, no dependence. |
| Regulatory status | Approved pharmaceutical in Russia since 1994. Multiple clinical trials and a meta-analysis in stroke. No Western-format RCTs — a regulatory and economic gap, not a scientific one. |
| Best stacked with | Selank to offset mild activation with anxiolytic balance. Pinealon for foundational neuroprotection alongside cognitive enhancement. P21 for structural neurogenesis — building new neurons alongside Semax's signaling enhancement. |
How Semax Works
The mechanism explains the practical pattern: why effects take days to appear, why the Russian protocols cycle rather than dose continuously, and why this is fundamentally different from stimulants.
BDNF: The Core Mechanism
A brain that learns and recovers well keeps its growth signals strong, particularly in the regions responsible for memory and executive function. Chronic stress, illness, and poor blood flow degrade this capacity: connections thin, networks lose flexibility, and the brain becomes less able to adapt.
Semax restores the conditions for growth. It increases the brain's primary growth signal — BDNF — strengthening the receptors that receive it, and shifts gene expression toward repair and vascular support (BDNF/TrkB upregulation¹). In the memory and executive function regions, this means:
- Stronger existing connections between neurons — established neural pathways become more efficient (synaptic potentiation¹)
- New physical connection points between neurons — creating architecture for new learning (dendritic spine formation¹)
- Better neuronal survival — protecting brain cells from stress, toxins, and oxygen deprivation
A 2018 study in 110 post-stroke patients provided direct human confirmation: Semax raised plasma BDNF levels regardless of when rehabilitation began, and higher levels correlated with faster functional recovery². The biomarker moves in the direction the mechanism predicts.
This also explains two practical things:
Why effects take days to appear. Semax changes which proteins brain cells produce — not temporarily flooding receptors. Gene expression takes time to manifest as noticeable cognitive improvement.
Why cycling is mandatory. Constant stimulation causes the brain to compensate by becoming less responsive — the growth signal receptors dial down their sensitivity (receptor desensitization). Regular off-periods let them reset.
Dopamine and Serotonin — Without the Stimulant Pattern
The ability to start tasks, hold information in mind, and sustain attention depends on how well certain brain circuits handle their chemical messengers — primarily dopamine and serotonin. In a fatigued or damaged brain, these systems either under-respond (producing apathy and difficulty initiating) or fire erratically (producing scattered attention and poor follow-through).
Stimulants force the brain to dump its dopamine reserves — a spike, then a crash, then a higher requirement next time for the same effect. Eventually the engine runs on empty.
Semax improves signal quality in these circuits without pushing them into stimulant territory. The circuits process and refresh their chemical messengers more effectively (dopamine/serotonin turnover³), but behaviour does not shift toward the jittery, stereotyped pattern seen with classical stimulants. Task initiation feels easier, attention holds longer, and cognitive output rises without cardiovascular strain or crash.
The analogy: stimulants are like redlining your engine to go faster. Semax is like upgrading the engine so it produces more power at normal RPMs.
Enkephalin Preservation
Semax also preserves the brain's own stress-buffering peptides — short molecules involved in pain modulation, reward, and emotional regulation — by slowing their breakdown (enkephalinase inhibition⁷).
The practical effect is smoother affect and better stress tolerance under cognitive load. The work feels less aversive — not because the task changed, but because the brain's stress-buffering chemistry has more room to operate.
Stress Buffering
Semax is derived from a fragment of ACTH, a stress hormone. A molecular tail eliminates the hormonal effects of the parent molecule while making the peptide resistant to breakdown (Pro-Gly-Pro stabilisation). Semax does not raise baseline cortisol or drive the adrenal glands under normal conditions.
Under stress, it buffers the response:
- At baseline (no stress): Semax does not change cortisol levels. The resting stress axis is left alone.
- Under acute stress: Semax reduces elevated cortisol by approximately 29–34%, prevents the adrenal glands from enlarging under chronic stress (adrenal hypertrophy prevention), and normalises stress-driven behavioural changes.
This positions Semax as a stress-protective signal: it increases adaptive capacity without acting as a sedative or stimulant. The practical implication is smoother performance under pressure and better recovery from demanding periods.
Inflammation Reduction
When blood flow to the brain is interrupted — or when low-grade inflammation persists from stress, past infections, poor sleep, or metabolic dysfunction — the initial insult is only part of the damage. A secondary wave of inflammatory activity spreads beyond the original injury zone. In chronic cases this persists long after the trigger is gone, manifesting as brain fog, cognitive fatigue, and difficulty concentrating.
When Semax was added to stroke care, healing and protective signals rose while inflammatory markers fell (anti-inflammatory cytokine shift⁵). More neurons survived oxygen deprivation, and oxidative damage was reduced.
The same mechanism points at chronic neuroinflammation: Semax quiets inflammatory activity that degrades cognitive signal quality, the direction the stroke-care markers moved — though that measured cohort is stroke, not chronic low-grade inflammation. Broad gene expression studies show this is not a single-target effect — Semax coordinates changes across immune response, vascular remodelling, and inflammatory signalling simultaneously⁵.
Semax Benefits
Focus and Mental Clarity
The most consistently reported benefit across both clinical literature and user communities. The reported effect is the kind of focus that makes it easier to start tasks, stay on them, and push through complex work without the typical mental resistance.
This is not the laser-focus-for-four-hours-then-collapse pattern of stimulants. Users describe it as turning down the noise — less mental static, clearer thinking, an easier time engaging with work that normally triggers procrastination. Stronger neural connections mean established pathways operate more efficiently; optimised dopamine handling means task initiation takes less activation energy.
Working Memory
Working memory — the ability to hold information in mind while actively using it — is a specific function Semax acts on through its effects in the prefrontal cortex. Losing a train of thought mid-sentence, forgetting the reason for walking into a room, or struggling to hold several variables in mind while solving a problem all run on this function.
Russian clinical studies in patients with chronic reduced blood flow to the brain showed improved attention, short-term memory, and mental flexibility on formal cognitive testing. Brain activity patterns (EEG) showed changes consistent with established cognitive-enhancing compounds but without the stimulant cardiovascular profile.
Cognitive Stamina
Users consistently report the ability to sustain quality cognitive work for longer periods. The typical afternoon fade — focus degrading into low-value busywork — either disappears or arrives much later in these reports. This is likely the combined result of stronger neural circuits (which don't fatigue as quickly), optimised dopamine handling (less depletion over the course of a day), and reduced inflammatory drag.
Neuroprotection
Semax was originally developed for stroke recovery, and this remains its strongest evidence base.
Acute stroke: A meta-analysis of Russian clinical trials showed that adding Semax (12–18 mg/day intranasal) to standard stroke care within hours of onset improved neurological deficits more rapidly over the first 10–14 days⁶. In one case series of 69 acute stroke patients, 83% showed symptom regression by mid-first week, with cognitive improvement beginning 4–7 days earlier than controls.
Long-term follow-up: A study of 120 patients with chronic reduced blood flow to the brain followed outcomes over three years¹⁰. Without prior stroke, cognitive scores recovered substantially on standard testing. With prior stroke history, improvement was twofold greater than controls at one year and threefold at three years — while control patients plateaued at 18 months, treated patients continued improving with repeated courses.
These doses (12–18 mg/day) are orders of magnitude higher than outpatient cognitive protocols. But the mechanism is the same at lower doses — the difference is scale and urgency, not biology. Semax creates the conditions for recovery; the work done during that window determines what gets consolidated.
Attention and Task Initiation
A research paper proposed Semax as a potential ADHD treatment based on its effects in the same dopamine and prefrontal circuits involved in attention regulation, and the BDNF signalling deficits observed in ADHD populations⁸. The mechanistic rationale is strong.
Russian paediatric practice includes Semax among neuroprotective agents used for attention-related conditions. The clinical experience exists — but it lives in Russian-language literature and has not been replicated in Western-format trials. No formal ADHD dataset has been published in English.
Users in biohacker communities report improvements in attention and task initiation, and the mechanism is consistent with these reports. Semax is not a replacement for established ADHD treatments, and no Western-format trial has tested it against them — the attention-use record sits in Russian clinical experience and community reports, not controlled comparison.
Semax Dosage Protocol
Semax dosage follows a simple principle: a low starting point, the minimum effective dose as the target, and regular breaks. This is not a compound where more is better.
Dosing
Semax is administered by subcutaneous injection or nasal spray. Use the peptide dosing calculator to determine exact injection volumes or spray counts from your product's concentration.
| Level | Daily Dose | Pattern | Duration |
|---|---|---|---|
| Starting | 200–300 µg SC | Morning only | 3–5 days to assess |
| Standard | 300–500 µg SC | Morning + optional late-morning booster | 10–14 day cycles |
| Higher range | 500–800 µg SC | Split across 2–3 doses | Short blocks only (7 days max) |
Nasal spray is an alternative at the same dose ranges for those who prefer to avoid injection. Most products deliver a specific µg per spray — check your product's concentration.
Most people settle into 300–400 µg/day as their working range. The typical effective dose is the minimum that produces noticeable improvement — not the maximum a person can tolerate.
The common scaffold:
- Days 1–3: 200 µg on waking, held flat while response is read.
- Day 4+: where focus fades before midday, a 100–200 µg late-morning addition brings the total to 300–400 µg/day.
- High-demand periods: up to 800 µg/day for 7 days at most, then back to maintenance.
Timing
Semax is dosed in the morning, which aligns with the natural cortisol peak and captures when focus is most needed. It is mildly activating — dosing after early afternoon can disrupt sleep.
A second dose lands before 1–2 PM. The breakdown products retain partial activity for 20–24 hours, so morning dosing covers the full workday.
Why Cycling Matters
This is where most people get it wrong. Semax is not a daily supplement taken indefinitely.
The protocol runs 10–14 days on, then 2–3 days off. When the brain's growth signal receptors receive persistent activation, they dial down their sensitivity — a compensation mechanism that makes the same dose progressively less effective. The off-periods serve two purposes:
- Receptor sensitivity reset. The brain's growth signal receptors return to normal sensitivity.
- Assessment checkpoint. Is the peptide still helping? Have subtle side effects accumulated? The break gives a clear comparison point.
This cycling pattern is built into Russian clinical protocols for a reason — decades of use have confirmed that intermittent courses outperform continuous dosing.
Dosing by Use Case
Cognitive enhancement (general): 200 µg morning, climbing to 300–400 µg/day. Standard 10–14 day cycles. Useful for demanding work periods, sustained focus, or clearing brain fog after illness or stress.
Focus and attention support: 300–600 µg/day SC, with nasal spray as an alternative at the same range. This is off-label and experimental — not a replacement for standard ADHD treatment, and untested against it in controlled trials.
Recovery support (post-viral, post-injury): a conservative 200 µg/day with a slow increase. Post-inflammatory states can respond more sensitively, so the entry point in this use case sits lower than usual.
N-Acetyl Semax Amidate and Adamax
Three versions of Semax exist. The active molecule is the same — what changes is how long it survives in the body before enzymes break it down.
Why the Modifications Exist
Regular Semax is a bare peptide. Enzymes in the bloodstream and nasal mucosa start degrading it immediately — which is why peak effects last only 2–4 hours and multiple daily doses are needed.
Two standard protective modifications extend this:
- N-Acetyl cap (front end): Blocks the enzymes that degrade peptides from the front, slowing breakdown and extending effective duration (aminopeptidase protection¹).
- Amide group (back end): Blocks degradation from the back end and improves absorption (carboxypeptidase protection¹). Also reduces the terminal charge, improving stability.
These are not exotic additions. Both modifications are well-understood techniques used routinely across peptide pharmacology to improve bioavailability. The active molecule reaching the brain is the same Semax — it just gets there more efficiently and lasts longer.
N-Acetyl Semax Amidate
N-Acetyl Semax Amidate carries both modifications and is the practical default for most people. It is the form most commonly sold by peptide suppliers (often labelled "NA-Semax-Amidate" or "NASA"). Longer duration means fewer daily doses. Better stability means more consistent effects and longer shelf life.
Unless cost is the primary concern or a shorter duration window is specifically needed, there is no compelling reason to use unmodified Semax over N-Acetyl Semax Amidate.
Adamax
Adamax goes a step further. It is a designer analogue that incorporates additional modifications at both ends, engineered for greater potency and stability beyond the standard N-Acetyl Semax Amidate form.
| Property | Regular Semax | N-Acetyl Semax Amidate | Adamax |
|---|---|---|---|
| Duration | 2–4 hours peak effect | 4–8 hours | 6–12 hours reported |
| Potency | Baseline | Increased | Described as "at least 2×" by users |
| Dosing frequency | 2–3× daily | 1–2× daily | Often 1× daily |
| Typical daily dose | 300–600 µg | 200–400 µg | 200–400 µg |
| Profile | Subtle, short | Smoother, longer | Strongest, most stimulating |
Which Variant to Choose
For most people: N-Acetyl Semax Amidate. Better bioavailability, longer duration, fewer doses per day. The sensible default.
Strongest cognitive push: Adamax delivers the longest duration and strongest subjective effects. But it is also the most stimulating — where N-Acetyl Semax Amidate already feels edgy at higher doses, Adamax amplifies that. Pairing it with Selank is the common community counter when irritability shows up.
Cost-sensitive or shorter-duration profiles: Regular Semax is cheapest, and its shorter window suits cases where effects need to clear by afternoon. It is also the form used in Russian clinical trials.
Note: Russian clinical trials studied unmodified Semax. N-Acetyl Semax Amidate and Adamax have not been through formal clinical evaluation — but given that the modifications are standard bioavailability enhancements to the same active molecule, this is a regulatory gap rather than a safety concern.
Side Effects and Safety
Across decades of Russian clinical use, the recorded adverse-event profile stays low at therapeutic doses. Formal testing reported no immune suppression, no allergic reactions, and no embryotoxic or mutagenic signals.
Common Side Effects
| Side Effect | Frequency | Reported response |
|---|---|---|
| Injection site irritation | Occasional | Rotating injection sites; normal and transient |
| Nasal irritation or dryness | ~7% of users (intranasal route) | On the nasal route: slower administration, alternating nostrils, or oily formulations |
| Headache or head pressure | Occasional, more at >600 µg/day | Eases with a lower dose and hydration |
| Feeling agitated or overstimulated | Occasional at higher doses | Eases with a lower dose or an added rest day |
| Sleep disruption | Common if dosed too late | Resolves when all dosing sits before 1–2 PM |
| Grumpiness or irritability | Reported at higher doses or during comedown | Eases at a lower dose; Selank is the common smoothing pair |
The flags that warrant stopping and a medical review
The signals that mark a stop-and-evaluate threshold:
- Severe or worsening headaches that do not respond to dose reduction
- Heart palpitations or chest discomfort
- Major mood changes (new depression, anxiety spikes, emotional instability)
- Any new neurological symptoms (vision changes, numbness, weakness)
Contraindications
The contraindicated profiles: pregnancy or breastfeeding (no safety data), active cardiovascular disease (limited data), a history of seizures (theoretical concern).
The caution profiles: bipolar disorder (insufficient data on mood destabilisation risk), concurrent use of multiple psychoactive substances (interaction data limited).
The Hair Loss Question
This comes up frequently in nootropic forums. Users report hair thinning or shedding while using Semax, attributing it to elevated BDNF.
The evidence: no clinical study has documented Semax-induced hair loss. Across decades of Russian pharmaceutical use and formal safety monitoring, hair loss does not appear as a documented side effect. Many Semax users simultaneously run complex nootropic stacks, experience stress, or use other compounds — attributing hair changes to Semax specifically is confounded by these concurrent factors. Anecdotally reported, clinically unconfirmed.
Dependency and Tolerance
Neither dependency nor withdrawal has been documented in available literature. Clinical work in chronic alcoholism found that Semax supported memory recovery and helped manage withdrawal-related cognitive deficits with no dependence signal⁹. With proper cycling, tolerance does not develop. Without cycling, receptor desensitisation can make the compound feel less effective — this reverses with a break. This is adaptation, not dependence.
What Users Report
Community experience adds texture that clinical papers cannot capture. Here is what consistent users report across nootropic communities.
"Clarity" Is the Universal Descriptor
Users do not describe Semax as stimulating. The word that appears across nearly every positive report is clarity:
"Halfway through the day it hit me. I realized I had been absolutely cranking through work. I was knocking out project after project, stuff I normally procrastinate on or do not even think about starting. I felt useful, energized, and locked in. Not jittery, just focused." — r/Nootropics
Another user: "A single dose helps me to be focused, productive, and efficient for hours. I've also noticed an improvement in my ADHD symptoms, which is a huge bonus."
The consistent theme: task completion improves, brain fog lifts within days, and the experience feels fundamentally different from stimulant-driven focus. No edge, no jitters, no crash.
Individual Variation Is High
Semax does not work for everyone. Non-responders exist. Some people take it for weeks and notice nothing meaningful. A proper course that produces nothing — 10–14 days, adequate dosing, morning timing — points to Semax not being the right tool for that person. That is a valid outcome, not a failure.
The Grumpiness Factor
Multiple sources mention irritability at higher doses or during the comedown:
"From experience I'd go easier on the semax and wind down the day with selank only. If you use too much semax it can make you grumpy both during use and when it comes off." — r/Nootropics
The Semax + Selank stack has become standard community practice partly for this reason — Selank's calming effect smooths out the edginess that Semax can produce at higher doses. When irritability shows up, a lower dose is the first lever, ahead of adding another compound.
These are self-reports, not controlled studies. Individual responses vary significantly.
FAQ
What is the recommended Semax dosage and protocol?
Semax is administered by subcutaneous injection, with nasal spray as an alternative route. The common pattern opens at 200–300 mcg per day for 3–5 days to read the response, then moves to a standard 300–500 mcg per day — most users settle around 300–400 mcg daily. Dosing sits in the morning or before early afternoon; evening use can disrupt sleep. Semax is cycled in 10–14 day runs with 2–3 days off between cycles. Most users run 2–4 cycles before a longer break of 1–2 weeks. N-Acetyl Semax Amidate, the most common variant, is typically dosed at 200–400 mcg once or twice daily following the same cycling pattern.
How long does Semax take to work?
Effects build over days as the brain increases BDNF production and gene expression shifts. Most people notice subtle improvements in focus and mental clarity within 2–3 days, with full effects developing over 1–2 weeks of consistent use. Some report task initiation improvements within the first day; others need a full week. This is not a quick-hit compound, and it does not behave like caffeine on the day it is taken.
Is Semax good for ADHD?
The mechanistic rationale is strong — Semax targets the same dopamine and prefrontal circuits involved in ADHD, and there is a published research paper proposing it as a potential treatment⁸. Some users report meaningful improvements in attention and task initiation. However, no clinical trial for ADHD has been conducted, and the published evidence remains in Russian-language literature. Semax is not a substitute for established ADHD medication, and it has never been tested against one in a controlled trial.
Is Semax a stimulant?
No. Stimulants force immediate release of neurotransmitter reserves, creating spikes followed by depletion. Semax gradually changes receptor sensitivity and gene expression — building infrastructure rather than dumping chemicals. There is no sudden activation, but over days: clearer thinking, easier focus, no jitteriness, tolerance, or crash.
What does Semax do to the brain?
Semax primarily increases the brain's main growth signal (BDNF), driving neuroplasticity — the ability to form and strengthen connections. It also improves how dopamine and serotonin circuits handle their messengers, reduces inflammatory activity that causes brain fog, and buffers the stress response without suppressing it. The result is enhanced cognitive capacity built from the ground up, not symptom masking.
Does Semax really work?
For stroke recovery and cerebrovascular disease, multiple clinical trials, a meta-analysis, and a 3-year follow-up of 120 patients consistently show meaningful benefit⁶¹⁰. For cognitive enhancement, the evidence is mechanistically coherent and supported by decades of Russian pharmaceutical use — but no Western-format trials exist. That absence reflects pharmaceutical economics (Semax is unpatentable, no commercial sponsor for billion-dollar trials), not a scientific gap. Community reports are consistently positive among responders, though non-responders exist.
Does Semax need to be cycled or can I take it continuously?
Yes — Semax is run in cycles, not continuously. The standard pattern is 10–14 days on, 2–3 days off. Cycling prevents the brain from compensating by downregulating BDNF receptors. Without breaks, increasing doses are needed for the same effect, and eventually the compound stops working. After 2–4 cycles, many users take a longer break of 1–2 weeks. This is not a safety concern but an effectiveness one — Semax works better with intermittent use. The cycling pattern is built into Russian clinical protocols and validated through decades of pharmaceutical use.
What is the difference between Semax, N-Acetyl Semax Amidate, and Adamax?
Same active molecule, different stability. N-Acetyl Semax Amidate adds standard protective modifications that improve bioavailability and extend duration from 2–4 hours to 4–8 hours — it is the practical default. Adamax goes further with additional modifications for even greater potency and 6–12 hour duration, but with a more stimulating profile. Regular unmodified Semax is cheapest and shortest-acting. N-Acetyl Semax Amidate is the common entry point.
Can Semax replace ADHD medication?
No. Some people use it as an adjunct alongside lower doses of stimulants, or for milder attention issues that do not meet full ADHD diagnostic criteria. That adjunct use sits outside any controlled trial and outside the established-medication pathway.
What the Evidence Actually Looks Like
Semax has a substantial evidence base — but almost all of it lives in Russian-language literature. This matters for understanding what you are reading and what you are not.
What exists:
- Multiple clinical trials in acute ischemic stroke, including a meta-analysis
- A 110-patient study correlating Semax with elevated plasma BDNF and functional recovery²
- A 3-year follow-up of 120 patients with chronic cerebrovascular disease¹⁰
- Controlled data in glaucoma showing structural and functional optic nerve protection¹²
- Clinical use in Russian paediatric neurology, chronic alcoholism recovery, and dermatology
- Formal pharmaceutical approval in Russia since 1994 with decades of post-marketing surveillance
- A clean safety profile across all studied populations — no documented serious adverse events attributable to Semax
What does not exist:
- Western-format randomised controlled trials for cognitive enhancement in healthy populations
- English-language ADHD datasets (Russian clinical experience exists but has not been published in English journals)
- Head-to-head trials for N-Acetyl Semax Amidate or Adamax
The absence of Western trials is not a scientific finding — it is an economic one. Semax is a natural peptide that cannot be patented. No commercial sponsor will fund the trial infrastructure required for regulatory approval in a compound anyone can manufacture. This reflects a structural reality of pharmaceutical economics, not a scientific verdict on safety or efficacy.
The drugs Semax is most often compared to — stimulants for attention, SSRIs for mood — have their own evidence problems that rarely get discussed. Independent analysis of FDA trial data has shown that antidepressants are barely more effective than placebos, with the published literature systematically overstating efficacy due to selective publication of positive trials¹³¹⁴. The asymmetry between how their evidence is treated and how peptide evidence is treated has more to do with patent economics than with science. Combination with Selank or other peptides is based on mechanism and clinical experience, not trial validation.
Related Topics
- Selank Guide — Companion anxiolytic peptide, often stacked with Semax
- NAD+ Guide — Cellular energy support that complements cognitive recovery
- Pinealon Guide — Neuroprotective peptide from the same Russian research tradition
- ARA-290 Guide — Neuroprotective peptide for nerve repair
- MOTS-c Guide — Mitochondrial peptide for metabolic and cognitive support
- Peptide Stacking Guide — How to combine peptides across five biological axes
- Peptide Reconstitution Calculator — How to prepare Semax for injection or intranasal use
- Peptide Dosing Calculator — Calculate exact spray counts and injection volumes
References
¹ BDNF/TrkB upregulation — Semax increases hippocampal BDNF mRNA and TrkB receptor expression; dendritic spine formation mediated by TrkB–PLCγ signalling: Eremin KO, et al. Brain Res. 2006;1117(1):54–60. PubMed 16996037
² Post-stroke BDNF elevation — 110-patient study; Semax raised plasma BDNF regardless of rehabilitation timing; higher BDNF correlated with faster functional recovery: Polunin GS, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):42–47. PubMed 29798983
³ Dopamine/serotonin turnover — Semax increases DA and 5-HT turnover in frontal cortex and hippocampus without stereotyped stimulant behaviour; no cardiovascular activation: Dolotov OV, et al. Neurochem Res. 2003;28(5):679–688.
⁴ Stress axis buffering (HPA) — Semax reduces stress-induced corticosterone by ~29–34%, prevents adrenal hypertrophy in maternal separation models, normalises HPA reactivity without baseline suppression: Fedorov VN, et al. Meditsinskiy Al'manakh. 2017;1(46):114–120.
⁵ Anti-inflammatory cytokine shift — Semax reduces IL-8 and CRP while elevating IL-10 and TGF-β1 in acute stroke patients; genome-wide transcriptional analysis shows coordinated changes across immune, vascular, and inflammatory gene networks: Medvedeva EV, et al. BMC Genomics. 2014;15:228. PMC 3987924
⁶ Acute stroke meta-analysis — Meta-analysis of Russian stroke trials; 12–18 mg/day intranasal; neurological deficit improvement more rapid at days 10–14; functional advantage persists to day 21; greatest benefit with early start and full 10-day course: Shmonin AA, et al. Vestnik Vosstanovitel'noy Meditsiny. 2018;2:81–88.
⁷ Enkephalinase inhibition — Semax inhibits the enzyme that degrades endogenous enkephalins; IC50 approximately 10 µM in vitro: Potaman VN, et al. Dokl Biochem Biophys. 2001;379:240–242. PubMed 11443939
⁸ ADHD hypothesis — Semax as potential ADHD treatment based on dopamine modulation in frontal circuits and BDNF signalling deficits in ADHD populations; no clinical trial conducted: Ashmarin IP, et al. Med Hypotheses. 2007;68(5):1055–1058. PubMed 16996699
⁹ Chronic alcoholism recovery — Semax supported memory recovery and managed withdrawal-related cognitive deficits; no dependence signal across course treatment: Potupchik T, Lopatina T, Lopatin V. Vrach. 2018;29(11):21–29.
¹⁰ 3-year cerebrovascular follow-up — 120 patients with chronic reduced cerebral blood flow; Semax group: 2.5× better functional recovery at 1 year, 3× at 3 years; controls plateaued at 18 months; treated patients continued improving with repeated monthly courses: Ivanova NE. Russian Neurosurgical Research Institute (Polenov). uMEDp.
¹¹ Post-stroke rehabilitation — Combination of Semax with electroneuromyostimulation produced substantially better recovery of drawing, attention, memory, and mental performance than stimulation alone: Sidorova SA, et al. Klinicheskaya Farmakologiya. 2012;21(4):106–109.
¹² Glaucoma/optic neuropathy — Controlled data showing structural and functional optic nerve protection with Semax 0.1% over 12-month follow-up: Alekseev VN, et al. Glaucoma. 2012. See also: Ioseliani OR, et al. Vestn Oftalmol. 2001;117(3):5–8. PubMed 11569188
¹³ Antidepressant efficacy — selective publication — Independent analysis of FDA trial data showing systematic overstatement of antidepressant efficacy due to non-publication of negative trials: Angell M. The Epidemic of Mental Illness: Why? The New York Review of Books. June 23, 2011.
¹⁴ Antidepressant evidence gaps — Further analysis of pharmaceutical economics and evidence distortion in psychiatric drug trials: Angell M. The Illusions of Psychiatry. The New York Review of Books. July 14, 2011.
Foundational Reviews
¹⁵ Dolotov OV, Inozemtseva LS, et al. "N-acetyl semax: neuroprotective and cognitive effects." Dokl Biol Sci. 2016. PMID 28254017
¹⁶ Gusev EI, Skvortsova VI. "Semax: neuroprotective properties and mechanisms of action." Zh Nevrol Psikhiatr. 2011. PMID 21988158
¹⁷ Agapova TY, Agniullin YV, et al. "Semax activates expression of genes encoding brain-derived neurotrophic factor." Bull Exp Biol Med. 2007. PMID 17595011
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.